{"product_id":"kenvue-swot-analysis","title":"Kenvue SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElevate Your Analysis with the Complete SWOT Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eKenvue, a leader in consumer health, boasts strong brand recognition and a diverse product portfolio, but faces intense competition and potential regulatory shifts. Understanding these dynamics is crucial for any strategic decision-maker.\u003c\/p\u003e\n\u003cp\u003eWant the full story behind Kenvue’s strengths, risks, and growth drivers? Purchase the complete SWOT analysis to gain access to a professionally written, fully editable report designed to support planning, pitches, and research.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIconic and Trusted Brand Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKenvue boasts an iconic and trusted brand portfolio, featuring household names like Aveeno, BAND-AID, Johnson's, Listerine, Neutrogena, and Tylenol. This diverse collection of well-established brands forms a powerful bedrock for sustained consumer loyalty and significant market presence.  For example, in 2023, Kenvue reported approximately $15.4 billion in net sales, underscoring the market's reliance on these trusted brands.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Market Leadership\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKenvue stands as the world's largest pure-play consumer health company, a powerful position built on substantial revenue and a truly global reach. This leadership is evidenced by its service to approximately 1.2 billion people across more than 165 countries, showcasing an unparalleled scale in the industry.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScience-Backed Innovation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKenvue's strength lies in its science-backed innovation, with products like Neutrogena and Band-Aid frequently recommended by healthcare professionals. This deep connection to scientific research fosters significant consumer trust and sets Kenvue apart in a competitive market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImproved Gross Profit Margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eKenvue demonstrated a strong performance in 2024, achieving a significant improvement in its gross profit margins, which expanded by 200 basis points. This enhancement is a direct result of the company's strategic focus on operational efficiency.\u003c\/p\u003e\n\u003cp\u003eThe gains in gross profit margin can be attributed to successful productivity improvements stemming from global supply chain optimization efforts. These initiatives streamlined operations and reduced costs, contributing to a healthier profit margin.\u003c\/p\u003e\n\u003cp\u003eFurthermore, Kenvue effectively realized value through its pricing strategies. By implementing thoughtful pricing approaches, the company was able to translate product value into improved profitability.\u003c\/p\u003e\n\u003cp\u003eKey factors contributing to this strength include:\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003e200 basis point expansion in gross profit margin in 2024.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eProductivity gains from global supply chain efficiency initiatives.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eFavorable value realization through strategic pricing.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResilient Core Segments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eKenvue's Self Care and Essential Health segments are proving to be strong performers, even when other parts of the business face headwinds. These areas are showing steady growth, providing a solid foundation for the company's financial stability.\u003c\/p\u003e\n\u003cp\u003eFor instance, in the first quarter of 2024, Kenvue reported that its Self Care business saw a 2.0% organic sales increase, driven by strong performance in pain care and digestive health. Similarly, Essential Health delivered a 1.5% organic sales growth during the same period, highlighting the consistent demand for these product categories.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eResilient Self Care:\u003c\/strong\u003e This segment, featuring brands like Tylenol and Imodium, continues to exhibit robust organic sales growth, demonstrating consumer reliance on these trusted products.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSteady Essential Health:\u003c\/strong\u003e The Essential Health division, encompassing products such as Aveeno and Band-Aid, also shows consistent positive momentum, contributing to overall revenue stability.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePillars of Financial Health:\u003c\/strong\u003e These core segments act as dependable revenue streams, offsetting potential volatility in other business units and supporting Kenvue's financial resilience.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBrand Trust, Global Reach, and Efficiency Fueling Consumer Health Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKenvue's strength is anchored in its extensive portfolio of globally recognized and trusted brands, including Aveeno, BAND-AID, Johnson's, Listerine, Neutrogena, and Tylenol. This powerful brand equity translates into significant consumer loyalty and a commanding market presence. The company's global scale is also a major asset, serving approximately 1.2 billion people in over 165 countries as the world's largest pure-play consumer health company.\u003c\/p\u003e\n\u003cp\u003eKenvue has demonstrated impressive operational efficiency, evidenced by a 200 basis point expansion in gross profit margins in 2024, driven by supply chain optimization and effective pricing strategies. This focus on productivity has directly improved profitability. Furthermore, key segments like Self Care and Essential Health show consistent organic sales growth, with Self Care up 2.0% and Essential Health up 1.5% in Q1 2024, providing a stable financial foundation.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eKey Strength\u003c\/th\u003e\n\u003cth\u003eSupporting Data\/Fact\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBrand Portfolio \u0026amp; Trust\u003c\/td\u003e\n\u003ctd\u003eIconic brands like Tylenol, Neutrogena, Aveeno\u003c\/td\u003e\n\u003ctd\u003eHigh consumer loyalty, market penetration\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal Scale\u003c\/td\u003e\n\u003ctd\u003eServes 1.2 billion people in 165+ countries\u003c\/td\u003e\n\u003ctd\u003eExtensive market reach, economies of scale\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperational Efficiency\u003c\/td\u003e\n\u003ctd\u003e200 bps gross profit margin expansion (2024)\u003c\/td\u003e\n\u003ctd\u003eImproved profitability, cost reduction\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSegment Resilience\u003c\/td\u003e\n\u003ctd\u003eSelf Care +2.0% organic sales (Q1 2024)\u003c\/td\u003e\n\u003ctd\u003eStable revenue, offsets other segment volatility\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a strategic overview of Kenvue’s internal and external business factors, examining its strengths in established brands, weaknesses in recent spin-off challenges, opportunities in emerging markets, and threats from competition and regulatory changes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eKenvue's SWOT analysis provides a clear roadmap for navigating market challenges and capitalizing on growth opportunities, easing the pressure of strategic uncertainty.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDeclining Sales in Skin Health \u0026amp; Beauty\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKenvue's Skin Health \u0026amp; Beauty segment has faced significant headwinds, with declining sales and volume observed throughout 2024 and into the first quarter of 2025. This underperformance directly hinders the company's overall revenue growth trajectory.\u003c\/p\u003e\n\u003cp\u003eFor instance, the company reported a 2.1% organic sales decline in this category for the full year 2024, further exacerbated by a 3.5% drop in unit volume. This trend continued into Q1 2025, with Skin Health \u0026amp; Beauty sales falling by 4.8% organically.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNegative Foreign Currency Headwinds\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKenvue has faced significant challenges due to unfavorable foreign currency movements, especially the strengthening U.S. dollar. This has directly impacted its reported net sales, creating a notable headwind for the company's financial performance.\u003c\/p\u003e\n\u003cp\u003eThe company has explicitly acknowledged these negative currency impacts, and they have been incorporated into its forward-looking financial projections. For instance, Kenvue's 2025 earnings outlook already accounts for the drag these currency headwinds are expected to impose on its results.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSoft Consumer Demand in Certain Categories\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKenvue has grappled with softer consumer demand in certain product categories. This subdued interest has impacted sales, particularly in areas sensitive to seasonal health trends.\u003c\/p\u003e\n\u003cp\u003eA prime example is the company's pediatric pain franchise, which saw a notable downturn in 2024. This decline was directly attributed to lower incidences of common childhood illnesses like colds, coughs, and flu, highlighting the impact of external health factors on demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImpact of Asset Impairments and Higher Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eKenvue experienced a significant drag on its 2024 performance due to substantial non-cash charges stemming from asset impairments. These impairments directly reduced operating income, impacting the company's bottom line and overall profitability.\u003c\/p\u003e\n\u003cp\u003eHigher interest expenses in 2024 also played a crucial role in weakening Kenvue's financial results. This increase in borrowing costs eroded profitability further, contributing to a noticeable decline in diluted earnings per share for the period.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eAsset Impairments:\u003c\/strong\u003e Kenvue recorded significant non-cash charges in 2024 due to asset impairments, negatively affecting operating income.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIncreased Interest Expenses:\u003c\/strong\u003e Higher borrowing costs in 2024 directly reduced profitability and diluted earnings per share.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eProfitability Decline:\u003c\/strong\u003e The combined impact of these factors led to a weaker overall financial performance in 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnsustainable Dividend Payout Ratio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eKenvue's dividend payout ratio has reached an concerning 140%, signaling a potential unsustainability for its dividend payments without significant improvements in earnings.  This elevated ratio suggests that the company is distributing more in dividends than it is earning, which is a red flag for long-term financial health.\u003c\/p\u003e\n\u003cp\u003eThis situation raises serious questions about the company's ability to maintain its current dividend levels moving forward, especially if earnings do not see a substantial uptick. Investors often view a payout ratio exceeding 100% as a sign of financial strain.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eUnsustainable Dividend:\u003c\/strong\u003e Kenvue's dividend payout ratio stands at 140%, indicating it pays out more in dividends than it earns.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eLong-Term Viability:\u003c\/strong\u003e This high ratio is not sustainable in the long run without considerable earnings growth.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eInvestor Concern:\u003c\/strong\u003e The current financial performance raises concerns about the reliability of future dividend payments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRevenue Decline and 140% Dividend Payout Raise Sustainability Concerns\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKenvue's Skin Health \u0026amp; Beauty segment is a significant weakness, experiencing a 2.1% organic sales decline in 2024 and a further 4.8% drop in Q1 2025, coupled with falling unit volumes. This underperformance directly impacts overall revenue growth. Additionally, unfavorable foreign currency movements, particularly a stronger U.S. dollar, have negatively affected reported net sales, a factor already accounted for in Kenvue's 2025 outlook. Softer consumer demand, exemplified by a downturn in the pediatric pain franchise in 2024 due to lower illness rates, also presents a challenge.\u003c\/p\u003e\n\u003cp\u003eThe company's financial health is further strained by substantial non-cash charges from asset impairments in 2024, which reduced operating income. Higher interest expenses in the same year also eroded profitability, contributing to a decline in diluted earnings per share. A critical concern is Kenvue's dividend payout ratio, which reached 140% in 2024, indicating that dividend payments exceed earnings, raising questions about long-term sustainability and investor confidence.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eSegment\/Factor\u003c\/td\u003e\n\u003ctd\u003e2024 Performance\u003c\/td\u003e\n\u003ctd\u003eQ1 2025 Performance\u003c\/td\u003e\n\u003ctd\u003eImpact\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSkin Health \u0026amp; Beauty (Organic Sales)\u003c\/td\u003e\n\u003ctd\u003e-2.1%\u003c\/td\u003e\n\u003ctd\u003e-4.8%\u003c\/td\u003e\n\u003ctd\u003eHinders revenue growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUnit Volume (Skin Health \u0026amp; Beauty)\u003c\/td\u003e\n\u003ctd\u003e-3.5%\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eWeakens sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eForeign Currency Impact\u003c\/td\u003e\n\u003ctd\u003eNegative\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eReduces reported net sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePediatric Pain Franchise\u003c\/td\u003e\n\u003ctd\u003eDownturn\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eAffected by lower illness rates\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAsset Impairments\u003c\/td\u003e\n\u003ctd\u003eSignificant non-cash charges\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eReduced operating income\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInterest Expenses\u003c\/td\u003e\n\u003ctd\u003eHigher\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eEroded profitability, reduced EPS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDividend Payout Ratio\u003c\/td\u003e\n\u003ctd\u003e140%\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eUnsustainable, raises investor concern\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eKenvue SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Kenvue SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality and actionable insights.\u003c\/p\u003e\n\u003cp\u003eThe preview below is taken directly from the full SWOT report you'll get. Purchase unlocks the entire in-depth version, offering a comprehensive understanding of Kenvue's strategic position.\u003c\/p\u003e\n\u003cp\u003eYou’re viewing a live preview of the actual Kenvue SWOT analysis file. The complete version, detailing all strengths, weaknesses, opportunities, and threats, becomes available after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":55610565820793,"sku":"kenvue-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/kenvue-swot-analysis.png?v=1754740084","url":"https:\/\/growthsharematrix.com\/products\/kenvue-swot-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}